September revenue rose more than 66% from July as the rebranded pharmacy adds adjunct products and fills prescriptions for the Health Lives Here app. DataMeds…
October 01, 2026
Key Points Sagimet’s license partner Ascletis reported results from a Chinese Phase 3 open-label extension study of denifanstat in moderate to severe acne. Among 240…
September 30, 2026
Vanda Reports Positive Phase 3 HETLIOZ Results in Delayed Sleep-Wake Phase Disorder
Key Points HETLIOZ (tasimelteon) met the primary endpoint in Vanda Pharmaceuticals’ Phase 3 trial for delayed sleep-wake phase disorder (DSWPD). After 28 days, patients taking…
September 28, 2026
Daré Bioscience Adds U.S. Patent Protection for DARE-HPV as Phase 2 Trial Advances
Key Points Daré Bioscience announced a new U.S. patent covering topical lopinavir-and-ritonavir formulations for HPV-related cervical conditions. Daré holds an exclusive U.S. license to the…
September 25, 2026
Novo Nordisk and Nanexa Sign €1.165 Billion Deal to Develop Longer-Acting Injections
Key Points Novo Nordisk has secured an exclusive global license to use Nanexa’s PharmaShell drug-delivery technology for certain peptide-based medicines. The collaboration covers up to…
September 24, 2026
From Hypothesis to Reimbursement: The Cancer Research That Reached Patients in 2026
Research institutions and cancer charities mark World Cancer Research Day every September 24, a designation built on one argument: cancer science needs sustained funding. That…
September 23, 2026
Psyence BioMed Invests Up to $5 Million in PsyLabs for Planned U.S. Ibogaine Program
Key Points Psyence Biomedical Ltd. agreed to invest up to $5 million in Psyence Labs Ltd., or PsyLabs. PBM has committed $2.4 million, with up…
September 23, 2026
Armata Pharmaceuticals Receives $3.7 Million in U.S. Department of War Funding for AP-SA02 Phase 3 Study
Key Points Armata Pharmaceuticals received an additional $3.7 million in non-dilutive funding from the U.S. Department of War for its AP-SA02 Phase 3 clinical program….
September 22, 2026
Vistagen Says Fasedienol Nasal Spray Showed Continued Improvement in Social Anxiety Extension Study
Key Points Vistagen released early results from a longer-term study of fasedienol nasal spray for people with social anxiety disorder. Participants could use the treatment…
Novo Nordisk (NVO) laid out its long-term growth ambitions at a capital markets day in London on Monday, and shareholders responded by marking the stock…
September 21, 2026
Armata’s AP-SA02 Phage Therapy Shows Genetic Diversity May Improve Activity Against Staph Infections
Key Points Armata Pharmaceuticals will present new AP-SA02 data at ISSSI 2026 showing that controlled genetic diversity in its bacteriophage therapy may help it kill…
September 21, 2026
Telix to Acquire ITM for US$1.65 Billion Upfront, Securing the Only Globally Scaled Supply of Lutetium-177
Telix Pharmaceuticals Limited (NASDAQ: TLX, ASX: TLX), a vertically integrated radiopharmaceutical company, announced on September 21, 2026 that it has signed a strategic agreement to…